Treace Medical Concepts, Inc. (TMCI)
NASDAQ: TMCI · Real-Time Price · USD
5.26
+0.48 (9.95%)
Nov 4, 2024, 12:54 PM EST - Market open
Company Description
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.
The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision.
In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot.
Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Treace Medical Concepts, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 23, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 516 |
| CEO | John Treace |
Contact Details
Address: 100 Palmetto Park Place Ponte Vedra, Florida 32081 United States | |
| Phone | 904 373 5940 |
| Website | treace.com |
Stock Details
| Ticker Symbol | TMCI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001630627 |
| CUSIP Number | 89455T109 |
| ISIN Number | US89455T1097 |
| Employer ID | 47-1052611 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| John T. Treace | Chief Executive Officer, Founder and Director |
| Mark L. Hair CPA | Chief Financial Officer |
| Aaron J. Berutti | Senior Vice President of Sales |
| Terry W. Lubben | Chief Operations and Supply Chain Officer |
| Taylor Erickson | Chief Information Officer |
| Scot M. Elder J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Nathan Minnich | Senior Vice President of Marketing |
| Daniel E. Owens | Chief Human Resources Officer |
| Dr. Sean F. Scanlan Ph.D. | Chief Innovation Officer |
| Shana Zink | Senior Vice President of Clinical Affairs and Reimbursement |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |
| May 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | ARS | Filing |